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Context: Published studies exploring the metabolic effects of Modified-Release 
Hydrocortisone (MR-HC) replacement in patients with adrenal insufficiency (AI).  
Objective: To compare metabolic effects of MR-HC with Standard Glucocorticoid (SG) 
replacement in adults with AI. Randomised control trials (RCTs) were meta-analysed; non-
RCT studies described narratively with critical appraisal.   
Data sources: PubMed/Medline, EMBASE, CINAHL and CENTRAL were searched to identify 
relevant articles, published before Aug 2019.  
Study selection: All study types that reported metabolic profile (including anthropometric, 
glucose and lipid-related parameters), on patients switched from SG to MR-HC replacement. 
Following independent screening from two reviewers, 390 studies were identified, of which 
9 studies were included for review (RCT, n=2; non-RCT, n=7).  
Data extraction: Two independent reviewers assessed each paper for bias and data 
extraction.   
Results: Meta-analysis from RCTs (n=2), 104 patients were switched from SG to MR-HC 
replacement. Combining treatment effects, at 3-months post-therapy switch there was 
significant reduction in body weight (-0.82kg; 95% CI: -1.24kg to -0.40kg; p<0.001) and 
HbA1c (-0.13%; 95% CI: -0.214% to -0.045%; p=0.003). In the sub-group with Diabetes Mellitus 
(DM), reduction in HbA1C was more pronounced (-0.52%; 95% CI: -0.82% to -0.23%; p<0.001). 
Non-RCT studies showed improved anthropometric measures and glucose metabolism up to 
48-months following switch from SG to MR-HC replacement.  
Conclusions: In adults with AI, replacement with MR-HC associates with significant 
improvements in anthropometric measurements and HbA1c compared with SG replacement, 










Effective management of adrenal insufficiency (AI), regardless of underlying aetiology, 
usually requires lifelong glucocorticoid replacement therapy1, 2. Ideally, glucocorticoid 
replacement regimes should mimic physiological diurnal patterns of plasma cortisol, with 
an early morning peak and mid-night trough3. Steroid replacement lowers overall risk of life-
threatening adrenal crisis4, a condition which previously had a 100% mortality rate prior to 
administration of pharmacological glucocorticoid replacement therapies5,6. Unfortunately 
however, despite overall improvements in mortality, administration of steroid replacement 
therapies in patients with AI still associates with an increased mortality rate7,8, metabolic 
dysfunction (including weight-gain and impaired glucose metabolism9) and immune 
dysfunction (including impairment of natural-killer cell function10).  
The underlying aetiology of the associated increased mortality and metabolic and associated 
with glucocorticoid replacement in AI remains incompletely understood and contentious. 
Possible mechanisms include chronic exposure to excessive glucocorticoid action, and 
mismatch between plasma profiles associated with exogenous steroid replacement and 
those reflective of physiological circadian rhythm of endogenous glucocorticoid11.  Data 
drawn from retrospective studies have suggested that increased morbidity and mortality 
could result from higher doses previously administered to AI patients, and the importance 
of tailoring regimes to patients with more emphasis on timing of intake12. 
Hydrocortisone (usually administered orally, three times per day) is used most commonly 
for steroid replacement in adults with AI both in the UK13, and worldwide14.  Modified-
Release Hydrocortisone, (MR-HC, brand name Plenadren, administered orally just once per 
day), used in <2% of patients in the UK currently13,  has delayed absorption from the gut. 
Plasma cortisol levels with exogenous MR-HC in AI demonstrate superior replication of the 
normal physiological diurnal and circadian rhythm of endogenous cortisol (in subjects with 
an intact hypothalamo-pituitary adrenal axis), compared with thrice-daily standard 
hydrocortisone replacement15.  MR-HC replacement regimes however still fail to replicate 
the physiological nocturnal rise in cortisol, the clinical importance of which is still not known 
11. 
Replacement with MR-HC in patients with AI may restore expression of clock genes regulated 
by the normal physiological circadian rhythm of endogenous cortisol16. Furthermore, MR-HC 




Despite the evidence outlined here showing the benefits of MR-HC in patients with AI, 
regarding metabolic profile, there are relatively few reported studies that compare directly 
the metabolic effects of MR-HC versus Standard Glucocorticoid (SG) replacement in patients 
with AI. Our objective, was to perform the first meta-analysis of these studies alongside a 
formal systematic review of the metabolic effects of MR-HC versus SG replacement in adult 
patients with AI. 
 
Methods and Materials 
Search Strategy: Systematic literature search performed on all articles published until July 
2019, using the online databases: Medline/PubMed; EMBASE; CINAHL, and; CENTRAL. 
(Search strategies detailed in supplementary appendix).  Keywords used in search 
strategies: (Adrenal Insufficiency OR Addison’s OR Hypopituitarism OR [“Adrenal” AND 
“Insufficiency”] OR “Addison” OR “Hypopituitarism”) AND (Glucocorticoids OR 
Hydrocortisone OR Cortisone OR Prednisolone OR “Glucocorticoids” OR “Hydrocortisone” OR 
“Cortisone” OR “Prednisolone”) AND (Plenadren OR Chronocort OR Delayed Action 
Preparations OR [“Dual” OR “Modified” OR “Delayed” OR “Sustained”] AND “Release”). 
There were no restrictions on language or time restrictions.  Search outputs were imported 
into Covidence18.  
Inclusion Criteria: For all identified papers, titles and abstracts were screened by two 
independent reviewers (CB and PH), to identify relevance. For those abstracts that included 
metabolic outcome measures in patients with AI treated with MR-HC, these articles 
proceeded to full text review. Following full text review, articles were included in the 
review if they satisfied four key inclusion criteria (table 1): 
1) Publication in peer-reviewed journal;  
2) Subjects aged 18 years or older;  
3) Any type of AI, switched from SG to MR-HC replacement; 
4) Metabolic outcome measures (anthropometric, glucose and lipid metabolism).  
Exclusion Criteria: We excluded any studies reporting on glucocorticoid usage for non-
endocrine conditions, and endocrine conditions other than AI.   
Our initial search revealed 390 abstracts, of which we eliminated 86 due to duplication. Of 
the 304 remaining articles, 295 were excluded (figure 1). Following application of inclusion 
and exclusion criteria, we included 9 relevant articles in our review.  
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Data Extraction: Data extraction consisted of a tabular summary of number of participants, 
duration of follow up, outcome measurements and corresponding quality assessments (table 
2). Primary outcomes included anthropometric measures (BMI and bodyweight) and glucose 
metabolism (change in HbA1c) in all patients. Secondary outcomes included serum lipids, 
and sub-group analyses on glycaemic changes in those patients with both AI and diabetes 
mellitus (DM). Units are reported for HbA1c as percentage glycosylated haemoglobin (%), as 
not all studies reported in SI unit of mmol/mol.  For serum lipids units are reported as mg/dL 
for consistency as the vast majority of studies reported in these units, and those studies 
that did not were converted to mg/dL.  
We present data from non-RCT studies (mean and standard error, median and range and 
standard error where possible) in summary tables, with p-values for statistical hypothesis 
testing. We contacted study authors for any missing data. Where missing data were not 
available from the study author, attempts were made to obtain approximations from 
digitising published graphs19.   
Quality Assessment of Studies: The quality of randomised controls was assessed using the 
Cochrane collaboration tool20, with the revised tool used for randomised cross-over trials21.  
The Newcastle Ottawa Scale was used for non-randomised studies22: a maximum score of 9 
could be assigned for each study, with a score of >6 considered to be of high quality.  Single-
arm studies were quality-assessed using an adapted tool with 4 main criteria: selection; 
ascertainment; causality, and; reporting23. For these studies, an assessment for each domain 
was made, followed by judgement of overall quality23.  
Statistical Analysis: We applied meta-analysis on data from RCTs (with 95% confidence 
intervals [95% CI]) to calculate overall treatment effect size, using fixed-effects or random-
effects model. We calculated 95% CI from sample size and standard deviation for those 
studies only reporting standard deviations. For variables with insufficient data reported, we 
contacted authors of the original studies, and utilized any additional data supplied.  
Between-study heterogeneity was assessed using I-squared, with a p-value of >0.10 set as a 
threshold for application of fixed-effects model, and a p-value ≤0.10 for application of 
random-effects model, where possible.  A p-value of <0.05 was considered statistically 
significant for individual tests.   
Regarding assessment of primary outcomes of changes in bodyweight, BMI and HbA1c in all 
patients, a Bonferroni corrected p-value of 0.0167 was set to preserve the overall type 1 
error rate at 0.05. Secondary outcomes and additional analysis of HbA1c change in DM were 
considered significant with an unadjusted p-value of <0.05. We did not perform any formal 
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tests for sensitivity analysis and publication bias due to insufficient data. We used a 






Study Characteristics: The initial literature searches retrieved 390 papers, with 9 papers 
meeting the inclusion criteria to proceed to this systematic review15,17,24-30. Just two trials 
meet criteria for inclusion in RCT meta-analysis15,17 (table 2). One RCT was a cross over trial 
with 60 participants from Sweden, all of whom had a confirmed diagnosis of primary AI. This 
study compared the metabolic effects of MR-HC with standard hydrocortisone replacement 
(administered three times per day), with data up to 3-months15. The other RCT was a parallel 
design from Italy with inclusion of patients with a confirmed diagnosis of either primary or 
secondary AI. This study included patients on MR-HC (n=46) and SG therapy (n=43). SG 
therapies included orally administered hydrocortisone or cortisone (administered either 
twice or thrice daily), with data up to 6-months17. 
Non-RCT studies included one prospective study from Germany with patients confirmed to 
have either primary or secondary AI, including those opting to switch to MR-HC (n=30), and 
those remaining on standard hydrocortisone (n=20) and followed up between 3 and 9 
months25. A further non-RCT was a retrospective cohort study from Italy with patients 
switched to MR-HC (n=53) and those remaining on standard hydrocortisone (n=47), with 
metabolic outcomes compared at baseline up to 48-months30.  
The single-arm studies all took place in Italy, with three prospective studies24,27,28 and two 
retrospective studies26,29. The single-arm prospective studies each included 19 participants. 
One prospective study consisted only of patients with primary AI treated with MR-HC for 12-
months28. The other two prospective studies consisted of patients with a mixture of primary 
and secondary AI, treated with MR-HC for a duration of between 6 and 12 months24,27. The 
two retrospective studies included between 14 and 49 patients, with follow up ranging 
between 24 and 36 months26,29.   
Risk of Bias in RCTs: The parallel RCT reported by Isidori and colleagues17 was assessed 
using the Cochrane risk of bias tool20 (see appendix). The study had a low risk of bias in all 
categories except blinding of participants: recruited patients were aware of their steroid 
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replacement (switch to once daily MR-HC or continued SG regime). The study authors 
outlined negative experience of prior trials that adopted a double-blind design for patients 
with AI17.   
The randomised cross-over RCT reported by Johannsson and colleagues15 was assessed using 
a revised tool for crossover trials21. There is some risk of bias in this study due to its open 
design, with no blinding of either participants or outcome assessors. The authors justify this 
design though, based on safety implications of adrenal crisis in a blinded patient randomized 
to placebo requiring doubling of dose15. The ongoing and continuous need for steroid 
replacement therapy in patients with AI meant it was not possible to include a ‘wash out’ 
period15. Lack of reported method of randomisation and allocation concealment may have 
contributed to bias risk, but there was low risk for all other categories explored.    
Meta-Analysis of RCTs: The two RCTs both provide data up to 3-months following switch 
to MR-HC15,17. Isidori and colleagues17 presented data as treatment effect difference 
between SG and switched MR-HC treatment groups in an ANCOVA analysis adjusted for age, 
subtype of AI, DM and smoking status. Data from the crossover trial reported by Johannsson 
and colleagues15 presented data as treatment difference, calculated from within-individual 
comparison of SG and MR-HC treatments. Johannsson et al.15 provided additional standard 
deviation data for treatment differences between groups. The cross-over trial was included 
in our meta-analysis since the authors reported treatment effect calculated from within-
individual comparison of treatments31. Isidori et al. provided unpublished data of glucose 
metabolism in patients with DM and subsequent treatment effect (raw data for meta-
analyses supplied in appendix).   
Meta-analysis of combined data from the two RCTs outlined (with crossover and parallel 
design), showed significant reduction in BMI and body weight in adult patients with AI 
switched from SG to MR-HC at 3-months (BMI -0.27kg/m2 [95% CI: -0.41 to -0.13]; p<0.001; 
body weight -0.82kg [95% CI: -1.24 to -0.40]; p<0.001). There was no significant between-
study heterogeneity for either BMI (I2=33.2%, Pheterogeneity=0.221, figure 2A) or body weight 
(I2=0%, Pheterogeneity=0.352, figure 2B). Meta-analysis of glucose metabolism showed a 
significant reduction in HbA1c in all patients at 3-months following switch from SG to MR-
HC replacement (HbA1C -0.13% [95% CI: -0.21 to -0.04]; p=0.003), with no significant 
between study heterogeneity (I2=0%, Pheterogeneity=0.643, figure 2C). A separate meta-analysis 
of HbA1c change at 3-months in those patients with DM showed a greater reduction in HbA1c 
(-0.52% [95% CI: -0.81 to -0.23]; p<0.001), with no evidence of between study heterogeneity 
(I2=0%, Pheterogeneity=0.505, figure 2D). The study by Isidori and colleagues also reported on 
metabolic treatment effects of MR-HC at 6-months following switch from SG replacement 
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therapy17. The effect sizes at 6-months showed significant reduction in BMI (-1.7kg/m2 [95% 
CI: -3.0 to -0.5]; p=0.008); body weight (-4kg [95% CI: -6.9 to -1.1]; p=0.008) and HbA1c (-
0.3% [95% CI: -0.5 to -0.1]; p=0.001)17.  Addition unpublished data provided by Isidori et al., 
showed a reduction of HbA1c in DM       (-0.78% [95% CI: -1.10 to -0.47]; p=0.002)17.    
Meta-analysis (fixed effects model) of secondary outcome measures showed no significant 
change in total cholesterol (-1.34mg/dl; [95% CI: -5.34 to 2.67]; p=0.513, figure 3A). As 
there was some evidence of between study heterogeneity (I2=70.7%, Pheterogeneity=0.065), a 
random effects meta-analysis was performed which also showed no significant change in 
total cholesterol (-4.64 mg/dl; [95% CI -16.08 to 6.82; p=0.428, figure 3B). Meta-analysis of 
separate serum lipids showed significant evidence of change in HDL cholesterol                    (-
4.4mg/dl; [95% CI: -6.38 to -2.42]; p<0.001, figure 4A), with no between study 
heterogeneity (I2%=47%, Pheterogenity=0.169).  Meta-analysis of LDL cholesterol showed no 
significant change (-0.197mg/dl; [95%CI -3.26 to 2.88]; p=0.900, figure 4B), with no 
significant between study heterogeneity (I2%=0, Pheterogeneity=0.636). Triglycerides showed 
evidence of change at 3-months (6.98 mg/dl; [95% CI: 0.781 to 13.188]; p=0.027, figure 4C), 
with no evidence of between study heterogeneity (I2=4.5%, Pheterogeneity=0.306). Meta-analysis 
of six-month data provided by Isidori et al. followed a similar pattern, with significant 
change in HDL cholesterol (-9mg/dl; [95% CI: -15 to -3]; p=0.002). There no significant 
changes in total cholesterol (0mg/dl; [95% CI: -16 to 15]; p=0.962), LDL cholesterol (7mg/dl; 
[95% CI: -8 to 21]; p=0.364) and triglycerides (7mg/dl; [95% CI: -35 to 21]; p=0.605)17. 
Bias Assessment of Non-RCTs: The Newcastle-Ottawa scale (NOS) used for cohort studies 
was used for assessing the risk of bias assessment of the non-RCTs22 (see appendix). Quinkler 
and colleagues reported a prospective study in which patients chose to either switch to MR-
HC or remain on their SG replacement therapy, thereby causing a selection bias.25 In the 
group that switched to MR-HC replacement, 6 had received (once-daily) prednisolone as 
their SG replacement regime prior to recruitment. None of the patients who opted to remain 
on SG therapy had previously had exposure to prednisolone therapy. Patients were followed 
up whenever their next clinic appointment was, causing a wide range of follow up time: 
patients switched to MR-HC had a median follow up time of 128 days (range 68-429 days); 
those who remained on SG therapy had a median follow up time of 338 days (range 98-498 
days). The differences in both follow up time and prior SG replacements between groups 
introduces a risk of bias in comparability. Overall, the study reported by Quinkler and 
colleagues,25 scored 5 on NOS scale indicating concerns of bias. 
The retrospective study reported by Guarnotta et al. (A)30 analysed patients referred to 
Palermo University between 2008 and 2013. There were baseline differences in 
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characteristics between the cohorts (including those switched to MR-HC of higher BMI and 
metabolic risk). Overall, the study reported by Guarnotta et al. (A)30 scored 6 on NOS scale 
indicating concerns of risk of bias.  
 
Narrative Synthesis of Non-RCTs: The prospective study reported by Quinkler et al.25 
showed significant reductions of BMI (p=0.003) and HbA1c (p=0.014) for patients switched 
from SG to MR-HC, with the retrospective study by Guarnotta et al. (A)30 also showing 
significant reductions in BMI (p=0.002) and HBA1c (p<0.001) for patients switched from SG 
to MR-HC (data in table 3). Neither study reported body weight as an outcome.  The control 
group remaining on SG (oral hydrocortisone) in the study by Quinkler et al.25 showed no 
significant changes across primary outcomes. However, over 48-months the control group 
on SG replacement in study by Guarnotta et al. (A) 30 showed significant increases in BMI 
(p<0.001) and HbA1c (p<0.020).   
Regarding secondary outcomes, Quinkler et al.25 showed a significant decrease in total 
cholesterol (p=0.016) in the group switched to MR-HC, but no change in the control SG group 
(p=0.332).  There were no significant changes in other serum lipids across the ‘switch to MR-
HC’ and control SG groups. The study by Guarnotta et al. (A)30 showed significant decreases 
in total cholesterol (p=0.006) and LDL cholesterol (p=0.005) at 48-months in the group 
switched to MR-HC therapy, and significant increases in LDL cholesterol (p=0.018) in the SG 
control group. There were no significant changes in HDL cholesterol or triglycerides in either 
group.   
Bias Assessment of Single-Arm Studies: There were 3 prospective single-arm studies24,27,28 
and 2 retrospective studies26,29, varying in size from 14 to 49 participants.  The study 
reported by Giordano et al.28 recruited 19 patients with primary AI, at a single centre in 
Italy, deemed low risk for bias across all domains (risk of bias table in supplementary 
appendix).  Ceccato et al. 24 recruited 19 patients with either primary or secondary AI with 
some risk of bias for causality due to a wide range of follow up time. The retrospective 
study by Frara et al.26 included 14 patients with secondary AI, and a focus on bone density 
and reporting bias related to metabolic measurements due to missing data. Guarnotta et al 
(B)29 recruited 49 patients and presented results separately for pre-diabetic and normal 
glucose tolerance patients and was considered low risk across all domains. The prospective 
study reported by Mongioi et al.27 had high risk of bias for ascertainment and causality. Some 
patients in this reported study were treatment naïve with recent diagnosis of AI.27 
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Narrative Synthesis of Single-Arm Studies: (Results for all single-arm studies are 
summarised in table 4). For primary outcomes, the largest study with 49 patients reported 
by Guarnotta et al. (B)29 showed a significant reduction in BMI after 36-months following 
switch to MR-HC compared to the group who remained on SG therapy. None of the other 
reported studies24,26-28 showed any significant changes in BMI. The studies reported by 
Guarnotta et al. (B)29 and Giordano et al.28 reported significant reductions in HbA1c at their 
final endpoints of 36-months and 12-months respectively following switch to MR-HC. 
Patients with primary AI but not secondary AI had significant improvement in HbA1c 
following switch to MR-HC in the study reported by Mongioi et al.27.  There were no reports 
of any significant changes in HbA1c in the other studies24,26.  The only paper to report on 
body weight was by Giordano et al.28, which showed no significant changes. 
For secondary outcomes, the studies by Ceccato et al.24 and Giordano et al.28 showed 
significant decreases in total cholesterol following switch to MR-HC. There was a significant 
decrease in LDL cholesterol in the study reported by Giordano et al.28. In the study reported 
by Guarnotta et al. (B)29 there was a significant decrease in HDL cholesterol following switch 
to MR-HC. There were no significant changes in any other serum lipids measurements across 

















This systematic review and meta-analysis of 2 randomised studies 15,17 showed significant 
improvement in all metabolic primary outcomes at 3 months after switching to MR-HC.  
There were additional improvements in glucose metabolism in patients with concomitant 
diabetes 15,17.  Two non-randomised studies 25,30 and 5 single-arm studies 24,26-29 supported 
these findings with the higher quality and larger sample size studies showing improved 
anthropometric measures and glucose metabolism up to 48 months post switching to MR-
HC.  
Both randomised trials 15,17 showed significant improvement across all primary outcomes, 
with the meta-analysis being primarily weighted by the crossover study, due to its smaller 
confidence intervals.  This would be expected in the crossover study 15 as patients act as 
their own controls, and there is large individual variation in response to steroids in AI 
patients 15.  Additionally the cross-over trial15 used only thrice-daily hydrocortisone in the 
control group and only primary AI patients, compared to hydrocortisone or cortisone as the 
control group and all types of AI in the RCT17, further contributing to variation in treatment 
effect size.  Sub-group analysis was not performed due to the small patient number, and 
analysis for secondary AI patients and patients on different glucocorticoid regimes prior to 
switch were only available for one study.   The ANCOVA treatment effect calculated in the 
Isidori study17 did use AI subtype as a covariate to partially account for this in combination 
with the Johansson study15 in meta-analysis.  Isidori et al17 used a conversion of 0.8mg 
hydrocortisone to 1mg cortisone which they stated as being per European Medicines Agency 
providing some adjustment for the effects of different SG replacement.    
 
The crossover trial was included in meta-analysis, despite its heterogeneity due to the 
limited number of randomised studies. The cross-over trial 15 is likely to have a carry-over 
effect as washout is not possible. The limited number of studies available is the main 
limitation to this analysis and would need repeating when further trials are performed. 
Whilst the RCT has a degree of carry-over effect as patients are converted from SG 
replacement to MR-HC, the cross-over trial has the additional carry-over when patients are 
switched from MR-HC back to hydrocortisone.  Carry-over effect creates uncertainty 
regarding treatment effect 31. In this case the carry-over possibly risks under-estimate of 
effect as MR-HC could potentially give long lasting benefit on switching back to 




The RCT showed additional benefit at 6 months17, with the individual paper itself 
commenting a treatment by time interaction starting at 3 months and improving further at 
6 months17.  Therefore, there is expected to be greater treatment effect beyond the 3-
month time point of meta-analysis, and further adequately powered randomised trials are 
required of longer duration to assess the long term effects of MR-HC on metabolic outcomes. 
 
The non-randomised studies 25,30 agree with the findings of the RCTs, but are both limited 
by selection bias.  In Quinkler et al. 25 patients selected what treatment they wanted with 
further limitation of patients not having a uniform follow-up time.  Guarnotta et al. (A) 30 
showed patients being switched to MR-HC being of greater metabolic risk than those 
remaining on SG therapy.  An advantage of this selection bias however, was the degree of 
improvement shown by high risk patients switched to MR-HC and the progressive metabolic 
risk shown by patients remaining on SG replacement 30.  The strength of these studies are 
the large sample sizes.  The 48 months follow up time in Guarnotta et al. (A) 30 provides the 
longest term data on the effects of MR-HC.  None of the single-arm studies showed 
significant change in BMI24,26-29, but studies with lower risk of bias paralleled the results of 
randomised and non-randomised studies with decrease in HbA1c 28,29. 
 
Across all studies there was a large range in effects observed for secondary outcomes.  Meta-
analysis showed decrease in HDL cholesterol, and increase in triglycerides at 3 months. 
Decreased HDL cholesterol persisted at 6 months in RCT 17 but increased triglycerides were 
not present at 6 months.  These findings could convey possible increase in cardio-metabolic 
risk 32, although individual studies had not calculated HDL/TC ratios for meta-analysis. Non-
randomised studies beyond 6 months show no significant change in HDL cholesterol or 
triglycerides 25,30, with evidence of decrease in total cholesterol 25,30, and additionally in LDL 
cholesterol up to 48 months 25.  Single-arm studies showed wide variation in effects on 
cholesterol 24,26-29.   
Prior clinical studies have explored the influence of glucocorticoid replacement regimes on 
HDL-C levels and cholesterol metabolism. Patients with secondary AI exposed to higher dose 
glucocorticoid regimes have been shown to have increased HDL-C levels without alteration 
in triglyceride levels 33, with an separate study showing that reduced cholesteryl ester 
transfer protein activity contributes to increased HDL-C levels in high dose glucocorticoid 
replacement regimes for patients with secondary AI 34. Glucocorticoid receptor antagonism 
in patients with Cushing’s have been shown to decrease HDL-C levels, but with increased 
efflux capacity per HDL-C particle 35.  These studies show a complex relationship between 
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glucocorticoid replacement regimes and HDL-C metabolism. Further studies are needed to 
explore the effects on HDL-C metabolism and how these changes affect cardiometabolic risk 
in both MR-HC regimes and SG regimes.    
The mechanism for how MR-HC mediates its metabolic improvements is not definitively 
understood.  Equivalent daily dose MR-HC to thrice daily hydrocortisone provides 20% less 
exposure to glucocorticoids per day 15, and has been cited as a possible mechanism for the 
clinical improvements 11,36. None of the studies performed an adjustment for these 
pharmacokinetics.  The significance of this decreased however is complex in relation to 
anthropometric measures as an observational study has shown no difference in BMI between 
high and low doses of hydrocortisone 37.   Decreased exposure to glucocorticoids in AI though 
have been shown to affect HDL levels in a dose dependent manner33.  Further clinical studies 
are needed to definitively assess if the metabolic outcomes from MR-HC are dependent on 
decreased glucocorticoid exposure, by using a 1.2mg MR-HC to 1mg hydrocortisone ratio or 
exposure to even higher doses.  
Removal of the inappropriate nocturnal exposure to glucocorticoids which occurs in thrice 
daily hydrocortisone regimes 15, could however provide the mechanism for the metabolic 
outcomes of MR-HC.  Evening doses of hydrocortisone have been shown to have a more 
profound hyperglycaemic effect 38, whilst rodent models have shown that converting from 
a diurnal regime to same daily dose continuous regime results in development of metabolic 
syndrome 39.   
An ancillary study of the RCT 17 has shown clock gene expression to be disrupted in AI 
patients on SG replacement compared to non-AI controls 16.  After switching to MR-HC for 
12 weeks disrupted clock gene expression returned to levels of non-AI controls, correlating 
with the improved metabolic outcomes 16.  More research is needed to further explore the 
clinical importance of restoring clock gene expression, and how this mediates improved 
anthropometric measures and glucose metabolism, and its effect on serum lipid levels. 
The evidence synthesised in this study showed high quality evidence available up to 6 
months, and lower quality evidence up to 48 months.  An additional long term study 
extending from the crossover trial showed no safety concerns over a 5 year period40, but 
had a drop our rate of 7/71 showing a need for further prospective data on long term use of 
MR-HC and prevention of adrenal crises.  Further adequately powered randomised trials over 
a time periods longer than 6 months are needed for more definitive evidence regarding the 
long term effects of MR-HC on metabolic outcomes in AI patients with calculated 
cardiometabolic risk in the form with lipoprotein and apolipoprotein ratios, alongside 
additional clinical outcomes such as hospital admissions and frequency of adrenal crises.   
14 
 
In conclusion this systematic review shows that from the available evidence to date, MR-HC 
has superior anthropometric and glucose metabolism compared to SG replacement, 
particularly for AI patients with concomitant DM. Further work is needed to assess if the 
changes in serum lipids lead to altered cardiometabolic risk. Additional adequately powered 
RCTs over a time period of at least 6 months comparing MR-HC to hydrocortisone including 
additional clinical outcome measures such as frequency of adrenal crisis and cardiovascular 
risk are required to definitively assess if MR-HC is an optimal form of glucocorticoid 
replacement.  Further work is needed to elucidate the mechanisms by which MR-HC 
mediates its metabolic improvements and changes to serum lipids, and the clinical 
significance of better matching the diurnal profile of cortisol in glucocorticoid replacement 
regimes.   
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Figures and Tables 
Table 1: PICOS Criteria for inclusion of studies: 
Population Adult Adrenal Insufficiency Patients 
Intervention Once daily modified release hydrocortisone 
Comparator Standard glucocorticoid replacement 
Outcome Metabolic measurements – primary outcome anthropometric 
measurement and glucose metabolism; secondary outcome serum lipids 





















Figure 1 – PRISMA Diagram Summarising Literature Search and Selection of Papers 
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Table 2: Main characteristics of Randomised control trials assessing the metabolic effects of modified release hydrocortisone 
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Figure 2 – Meta-Analysis Graphs of Randomised Control Trials at 3 months 
 
 
Figure 2A: Forest Plot of Randomised Controlled Trials at 3 months of change in 
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Figure 2B: Forest Plot of Randomised Controlled Trials at 3 months of change in 
Bodyweight (kg) post switching from standard glucocorticoid replacement to 




Figure 2C: Forest Plot of Randomised Controlled Trials at 3 months of change in 
HbA1c (%) in all patients post switching from standard glucocorticoid 
replacement to once daily MR-HC 
 
 




























Figure 2D: Forest Plot of Randomised Controlled Trials at 3 months of change in 
HbA1c (%) in diabetic patients post switching from standard glucocorticoid 










































Meta-Analyses of Secondary Outcomes in Randomised Trials  
 
Figure 3A: Forest Plot of Randomised Controlled Trials at 3 months of change in 
total cholesterol (mg/dL) in fixed effects meta-analysis post switching from 
standard glucocorticoid replacement to once daily MR-HC 
 
 























Switching to MR-HC Reduces Total Cholesterol (mg/dl) Switching to MR-HC Increases Total Cholesterol (mg/dL)
0-24 24
NOTE: Weights are from random effects analysis



























Figure 3B: Forest Plot of Randomised Controlled Trials at 3 months of change in 
total cholesterol (mg/dL) in random effects meta-analysis post switching from 
standard glucocorticoid replacement to once daily MR-HC 
 
 
Figure 4A: Forest Plot of Randomised Controlled Trials at 3 months of change in 
HDL cholesterol (mg/dL) in fixed effects meta-analysis post switching from 
standard glucocorticoid replacement to once daily MR-HC 
 




























Figure 4B: Forest Plot of Randomised Controlled Trials at 3 months of change in 
LDL cholesterol (mg/dL) in fixed effects meta-analysis post switching from 
standard glucocorticoid replacement to once daily MR-HC 
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Figure 4C: Forest Plot of Randomised Controlled Trials at 3 months of change in 
triglycerides (mg/dL) in fixed effects meta-analysis post switching from standard 



















































































































































































































[p=0.005] [p=0.284] [p=0.751] 
*Expressed as median and range 
†Expressed as mean and (standard error) 





















































































































































































































































































































































































































^Extracted data from published graph using WebPlotDigitizer19 
*Expressed as median and range 
**Reported as median, range not extractable from graph using WebPlotDigitizer19 
†Expressed as mean and standard error 
~Expressed as median and inter-quartile range  











Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to July 19, 2019> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Adrenal Insufficiency/ (12244) 
2     exp ADDISON DISEASE/ (4631) 
3     exp Hypopituitarism/ (8996) 
4     (Adrenal* and insufficien*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading 
word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier, synonyms] (12873) 
5     addison*.mp. (6180) 
6     hypopituitar*.mp. (9214) 
7     1 or 2 or 3 or 4 or 5 or 6 (29263) 
8     exp Glucocorticoids/ (186805) 
9     exp HYDROCORTISONE/ (71612) 
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10     exp CORTISONE/ (19554) 
11     exp PREDNISOLONE/ (49837) 
12     (Glucocorticoid* or hydrocortisone* or prednisolone* or cortisone*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, synonyms] (226891) 
13     8 or 9 or 10 or 11 or 12 (308920) 
14     7 and 13 (6829) 
15     plenadren.mp. (10) 
16     Chronocort.mp. (10) 
17     exp Delayed-Action Preparations/ (45544) 
18     ((Dual or Modified or Delayed or Sustained) and Release).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier, synonyms] (77539) 
19     15 or 16 or 17 or 18 (98948) 




Database: Embase Classic+Embase <1947 to 2019 July 22> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Adrenal Insufficiency/ (13209) 
2     exp ADDISON DISEASE/ (7517) 
3     exp Hypopituitarism/ (13811) 
4     (Adrenal* and insufficien*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword, floating subheading word, candidate term word] (22900) 
5     addison*.mp. (9334) 
6     hypopituitar*.mp. (15686) 
7     1 or 2 or 3 or 4 or 5 or 6 (43253) 
8     exp Glucocorticoids/ (749779) 
9     exp HYDROCORTISONE/ (138404) 
10     exp CORTISONE/ (38150) 
11     exp PREDNISOLONE/ (126581) 
12     (Glucocorticoid* or hydrocortisone* or prednisolone* or cortisone*).mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (422124) 
13     8 or 9 or 10 or 11 or 12 (787106) 
14     7 and 13 (16984) 
15     plenadren.mp. (38) 
39 
 
16     Chronocort.mp. (38) 
17     exp Delayed-Action Preparations/ (7819) 
18     ((Dual or Modified or Delayed or Sustained) and Release).mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (118067) 
19     15 or 16 or 17 or 18 (118093) 




Date Run: 23/07/2019 15:22:34 
Database: Cochrane CENTRAL  
ID Search Hits 
#1 Adrenal insufficiency 640 
#2 Adrenal* AND insufficien* 1090 
#3 Hypopituitary 124 
#4 Hypopituitar* 342 
#5 #1 OR #2 OR #3 OR #4 1412 
#6 MeSH descriptor: [Adrenal Insufficiency] explode all trees 215 
#7 MeSH descriptor: [Hypopituitarism] explode all trees 280 
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#8 #5 OR #6 OR #7 1585 
#9 MeSH descriptor: [Glucocorticoids] explode all trees 4298 
#10 glucocorticoid* 8400 
#11 MeSH descriptor: [Hydrocortisone] explode all trees 5750 
#12 hydrocortisone* 9157 
#13 MeSH descriptor: [Cortisone] explode all trees 127 
#14 cortisone* 599 
#15 MeSH descriptor: [Prednisolone] explode all trees 4504 
#16 prednisolone* 7024 
#17 #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 23634 
#18 #8 AND #17 652 
#19 MeSH descriptor: [Delayed-Action Preparations] explode all trees 6300 
#20 plenadren* 1 
#21 chronocort* 10 
#22 (Dual* OR Modified* OR Delayed* OR Sustained*) AND Release* 11779 
#23 #19 OR #20 OR #21 OR #22 14073 
#24 #18 AND #23 60 
 
CINAHL Search Strategy 
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# Query Limiters/Expanders Last Run Via Results 
S18 S11 AND S17 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 5 
S17 
S12 OR S13 OR S14 
OR S16 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 6,800 
S16 
"(Dual or modified 
or delayed or 
sustained) and 
release" 
Search modes - 
SmartText 
Searching 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 1,546 
S15 
"(Dual or modified 
or delayed or 
sustained) and 
release" 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  








Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 6,793 
S13 "chronocort" 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 2 
S12 "plenadren" 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 1 
S11 S9 AND S10 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  




S10 S1 OR S2 OR S3 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 1,736 
S9 
S4 OR S5 OR S6 OR 
S7 OR S8 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 21,287 
S8 "prednisolone" 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 3,606 
S7 "cortisone" 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  





Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 7,145 
S5 "glucocorticoids" 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  











Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  
Database - CINAHL 
Complete 16,866 
S3 "addison" 
Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  







Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  







Search modes - 
Boolean/Phrase 
Interface - EBSCOhost 
Research Databases  
Search Screen - 
Advanced Search  






Risk of Bias Assessments 
 





























2012, 15  


















































at start of 
study 
Comparabili
ty of cohorts 




















Selected group of 




whether to be 
exposed or 


































, 2019 30 
 Patients 
exposed to MR-









Yes (1 star) Not matched 



























d therapy to 
MR-HC (1 
stars) 





















Low risk Low risk Some 
concerns 








Low risk Low risk Low risk Low risk Low risk 
Mongioi, 
2018 27 














nbodyweight bmi lci bmi uci bmi nbmi hba1c% 
Isidori 2018 -1.5 -3 0 78 -0.7 -1.4 0 78 -0.1 
Isidori 2018 -4 -6.9 -1.1 78 -1.7 -3 -0.5 78 -0.3 


































Isidori 2018 -12 -24 0 -8 -13 -2 -3 -15 9 
Isidori 2018 0 -16 15 -9 -15 -3 7 -8 21 
Johannsso
n 















Separate extraction of diabetic patients 
Study year hba1c% lci hba1c uci hba1c nhba1c months 
Isidori 2017 -0.395 
-
0.8693113* 
0.079311* 15 3 
Isidori 2017 -0.784 
-
1.0975942* 
-0.47041* 15 3 
Johannsson 2012 -0.6 -0.971877* -0.22812* 10 3 
 
*Initially Reported as Standard Deviation, confidence interval calculated 
Johannsson et al. provided additional data of standard deviation of treatment effects.  Isidori et al. 
provided additional data of subgroup of diabetic patients. 
Johannson et al presented data as treatment difference calculated from within individual-comparison 
of treatments 
Isidori et al presented data as treatment difference calculated from ANCOVA analysis adjusted for age, 
sex, diabetes mellitus, type of adrenal insufficiency, and outcome at baseline (additionally adjusted for 
smoking status for HbA1c and serum lipids) 
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Code used in Stata for meta-analysis 
* this produces BMI meta-analysis 
metan bmi lcibmi ucibmi if months==3, fixed label(namevar= study, yearvar= year) 
favours(Treatment reduces BMI # Treatment increases BMI) 
* this produces bodyweight meta-analysis 
metan bodyweightkg lcibodyweight ucibodyweight if months==3, fixed label(namevar= 
study, yearvar= year)favours(Treatment reduces bodyweight # Treatment increases 
bodyweight) 
* this produces HbA1c meta-analysis for both data sets 
metan hba1c lcihba1c ucihba1c if months==3, fixed label(namevar= study, yearvar= 
year)favours(Treatment reduces HbA1c # Treatment increases HbA1c) 
* this produces cholesterol meta-analysis fixed effects* 
metan totalcholesterol lcitotchol ucitotchol if months==3, fixed label(namevar= 
studyauthor, yearvar= yearpublished)favours(Treatment reduces total cholesterol # 
Treatment increase total cholesterol) 
* this produces cholesterol meta-analysis random effects* 
metan totalcholesterol lcitotchol ucitotchol if months==3, random label(namevar= 
studyauthor, yearvar= yearpublished)favours(Treatment reduces total cholesterol # 
Treatment increase total cholesterol) 
* this produces HDL cholesterol meta-analysis* 
metan hdlcholesterol lcihdlchol ucihdlchol if months==3, fixed label(namevar= studyauthor, 
yearvar= yearpublished)favours(Treament reduces HDL cholesterol # Treatment increases 
HDL cholesterol) 
* this produces LDL cholesterol meta-analysis* 
metan ldlcholesterol lcildlchol ucildlchol if months==3, fixed label(namevar= studyauthor, 
yearvar= yearpublished)favours(Treatment reduces LDL cholesterol # Treatment increases 
LDL cholesterol) 
* this produces triglycerides meta-analysis* 
 metan triglycerides lcitri ucitri if months==3, fixed label(namevar= studyauthor, yearvar= 
yearpublished) favours(treatment reduces triglycerides # Treatment increases triglycerides) 
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